Written Question · S4W-00021 · Session 4
Whether the Scottish Medicines Consortium proposes to take action in light of the study in The New England Journal of Medicine claiming tha…
The question
To ask the Scottish Executive whether the Scottish Medicines Consortium proposes to take action in light of the study in The New England Journal of Medicine claiming that bevacizumab is as effective as ranibizumab in the treatment of wet macular degeneration.
The answer
The Scottish Medicines Consortium (SMC) appraises all newly licensed medicines for clinical and cost-effectiveness and publishes advice for NHSScotland. The SMC does not appraise a medicine to treat a condition for which the pharmaceutical company that manufactures it does not hold a marketing authorisation (license) for the treatment of that condition.
Whilst bevacizumab (Avastin) is licensed for the treatment of other conditions, it is not licensed for the treatment of eye conditions. Responsibility for obtaining a marketing authorisation for bevacizumab to treat wet age-related macular degeneration rests with the pharmaceutical company that manufactures it. The pharmaceutical company would then be able to submit clinical and cost-effectiveness evidence for consideration by the SMC.
Whilst bevacizumab (Avastin) is licensed for the treatment of other conditions, it is not licensed for the treatment of eye conditions. Responsibility for obtaining a marketing authorisation for bevacizumab to treat wet age-related macular degeneration rests with the pharmaceutical company that manufactures it. The pharmaceutical company would then be able to submit clinical and cost-effectiveness evidence for consideration by the SMC.
In the Official Report
No contribution in the Official Report cites S4W-00021 by reference.